Kexi Wang

Kexi Wang

Associate

Technology Transactions

Dr. Kexi Wang is an associate in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where her practice focuses on technology transactions and corporate law. Prior to attending law school, Kexi conducted doctoral research on the regulatory mechanism of mitosis, where she gained research experience in cell biology, molecular biology, and biochemistry.

Experience

Education

J.D., Harvard Law School, 2019Cum Laude
Ph.D., Biology, University of Toledo, 2014
B.S., Medical Laboratory Tests and Analysis, Shanghai Jiaotong University, School of Medicine, 2009

Admissions

State Bar of California

Credentials

Education

J.D., Harvard Law School, 2019Cum Laude
Ph.D., Biology, University of Toledo, 2014
B.S., Medical Laboratory Tests and Analysis, Shanghai Jiaotong University, School of Medicine, 2009

Admissions

State Bar of California

Recent Insights

Client Highlights

On August 22, 2024, Stryker, a global leader in medical technologies, announced a definitive agreement to acquire Vertos Medical Inc., a privately held company providing a minimally invasive solution for treating chronic lower back pain caused by lumbar spinal stenosis. Wilson Sonsini Goodrich & Rosati advised Vertos on the transaction.

Learn More

Client Highlights

On January 4, 2024, Stemline Therapeutics, Inc. (Stemline), a wholly owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, and Insilico Medicine (Insilico), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, announced they have entered into an exclusive licensing agreement granting Stemline global rights to develop and commercialize a novel, small molecule KAT6A inhibitor designed using Insilico's AI platform as a potential treatment for hormone sensitive cancers and other oncology indications. Under the terms of the agreement, Stemline will pay to Insilico a $12 million upfront payment; potential development, regulatory, and commercial milestones in excess of $500 million; and royalties.

Learn More